Cost of Poor Quality Calculator
Estimate your annual cost of poor quality — scrap, rework, and recall exposure — then see the illustrative ROI band of moving up one maturity level, anchored to the reductions FDA cites in its 2025 quality-economics white paper (defects −50%+, waste −75%). A business-case aid, not a guarantee.
WHAT THIS CALCULATES
The annual cost your quality problems are already imposing — scrap, rework and recall exposure added together — and, alongside it, an illustrative recovery if defects and waste fell by the amounts the FDA/OPQ 2025 case studies reported. It turns a quality argument into a number a finance conversation can use.
THE METHOD
CoPQ = (units × unitCost × defectRate) + reworkCost + recallExposure- units
- annual units produced
- unitCost
- fully-loaded cost per unit — materials, labour, overhead, not just materials
- defectRate
- the share of production scrapped or rejected, as a percentage
- reworkCost
- annual cost of reprocessing, re-inspection and re-testing
- recallExposure
- annual recall and complaint-handling cost, including field actions
The recovery figure applies the reductions observed in the FDA/OPQ (2025) case studies — defects down more than 50%, waste down 75% — to scrap, rework and recall respectively. That is a directional business case drawn from other companies’ results, not a forecast of yours.
THE INPUTS, AND WHAT THEY MEAN
- Annual units
- Units produced in a year for the site or line you are arguing about. Keep the scope tight — a site-wide number mixed with a line-specific defect rate produces a figure that is wrong in both directions.
- Cost per unit
- Fully-loaded, not bill-of-materials. A scrapped unit destroys the labour, utilities, QC testing and overhead already spent on it, which is usually several times the material cost.
- Defect rate
- The proportion of units scrapped, rejected or written off. Use your actual batch-disposition data, not the specification limit.
- Rework cost
- What reprocessing actually costs annually — labour, re-testing, re-release, and the deviation and investigation time each event drags behind it.
- Recall exposure
- Annual recall, complaint and field-action cost. Most sites underestimate this because the investigation, regulatory reporting and remediation hours are booked elsewhere.
Estimate your cost of poor quality — and the ROI of maturity.
Enter your figures. SPEQ estimates your annual cost of poor quality, then shows the illustrative recovery from moving up one maturity level, anchored to the reductions FDA cites in its 2025 quality-economics white paper. This is a business-case aid, not a guarantee.
Scrap cost is derived from units × cost/unit × defect rate. Rework and recall exposure are entered directly. All figures stay in your browser.
HOW TO READ THE OUTPUT
- ›The output is an order-of-magnitude estimate for prioritisation, not an accounting figure. Its job is to establish whether the quality problem is worth six figures or seven before anyone commissions a proper costing.
- ›CoPQ is systematically understated in most organisations because the largest components — investigation hours, delayed release, lost capacity, and management attention — are absorbed by departments that never book them as quality costs.
- ›The recovery band is illustrative and cites other organisations’ published results. Present it as "this is what comparable improvements achieved elsewhere", never as a projection of your own return.
- ›Scrap is usually the smallest and most visible line. If recall exposure or rework dominates your total, that is the argument — and it points at detection and prevention rather than at the production line.
WORKED EXAMPLE
A site making 100,000 units a year at $50 fully-loaded cost, scrapping 2%, with $250,000 of annual rework and $400,000 of recall and complaint exposure.
- Annual units
- 100,000
- Cost per unit
- $50
- Defect rate
- 2%
- Annual rework cost
- $250,000
- Recall / complaint exposure
- $400,000
Scrap is only $100,000 of the $750,000 — the visible loss is the smallest part. Rework and recall exposure together are 87% of the total, which says the money is going on finding and fixing problems after the fact rather than on the units themselves. That reframes the investment case away from the production line and towards detection, deviation handling and prevention.
REGULATORY BASIS
- FDA/OPQ Quality Management Maturity (2025)
- The case studies behind the recovery percentages, and the argument that quality maturity has measurable operational and financial consequences.
- ICH Q10 — Pharmaceutical Quality System
- Places continual improvement and management review at the centre of the quality system; CoPQ is one way to give management review something quantified to act on.
LIMITATIONS — READ BEFORE YOU RELY ON THIS
- ›This is an analytical aid, not a validated system, and its output is an estimate rather than an accounting figure. Reproduce the calculation in your own finance model before it supports a funding decision — the formula and the cited reduction percentages are published above so you can.
- ›It uses a single blended cost per unit and a single defect rate. A site with several products at different margins needs the calculation run per product, not averaged.
- ›The recovery figures come from other organisations’ published case studies. They are a directional argument, not a forecast, and they assume improvements you have not yet made.
- ›It counts nothing for lost capacity, delayed launches, customer attrition or the regulatory consequences of a compliance failure — all of which can exceed every line it does count.
Get the regulatory signal behind the calculation
New guidance, enforcement, and inspection findings touching FDA OPQ (2025) and its neighbours — distilled into the free Weekly GxP Briefing.